The present study demonstrated that high tumor 18F-fluorodeoxyglucose metabolism was associated with reduced DRFS and OS after adjusting for standard prognostic factors in patients with ER-positive, HER2-negative breast cancer treated with anthracycline-based NCT, followed by adjuvant endocrine therapy. This evidence concerns the gene ERBB2 and breast carcinoma.